Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) Chairman Lou Reese purchased 100,000 shares of Vaxxinity stock in a transaction dated Thursday, June 16th. The stock was acquired at an average price of $1.99 per share, for a total transaction of $199,000.00. Following the completion of the acquisition, the chairman now owns 51,737,344 shares of the company’s stock, valued at approximately $102,957,314.56. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Lou Reese also recently made the following trade(s):
- On Wednesday, April 27th, Lou Reese purchased 4,807 shares of Vaxxinity stock. The stock was acquired at an average price of $3.58 per share, for a total transaction of $17,209.06.
VAXX traded up $0.01 during trading on Tuesday, hitting $2.09. 676,877 shares of the stock were exchanged, compared to its average volume of 681,918. The firm has a 50 day simple moving average of $4.00 and a 200 day simple moving average of $5.11. Vaxxinity, Inc. has a 1 year low of $1.86 and a 1 year high of $22.77. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 0.09.
Separately, Evercore ISI initiated coverage on Vaxxinity in a report on Wednesday, April 27th. They set an “in-line” rating on the stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VAXX. FNY Investment Advisers LLC bought a new stake in Vaxxinity during the 4th quarter valued at $27,000. Geode Capital Management LLC bought a new stake in Vaxxinity during the 4th quarter valued at $382,000. ETF Managers Group LLC bought a new stake in Vaxxinity during the 4th quarter valued at $211,000. Goldman Sachs Group Inc. bought a new stake in Vaxxinity during the 4th quarter valued at $1,240,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Vaxxinity during the 4th quarter valued at $5,619,000. Institutional investors own 15.82% of the company’s stock.
About Vaxxinity (Get Rating)
Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.
- Get a free copy of the StockNews.com research report on Vaxxinity (VAXX)
- Should Silver Stocks Be A Part Of Your Portfolio?
- ABM Industries, A Clean Play For Dirty Economic Times
- This Still Isn’t A Buyable Bottom For Stocks
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
- Two Defensive Stocks To Get Aggressive With
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.